Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China · Delayed Price · Currency is CNY 99.93
+3.13 (3.23%)
May 29, 2026, 3:00 PM CST
SHA:688266 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 497.93 | -162.95 | -137.83 | -278.58 | -457.33 | -451 |
Depreciation & Amortization | 49.63 | 49.63 | 55.6 | 54.04 | 66.37 | 50.77 |
Other Amortization | 5.97 | 5.97 | 5.73 | 6.36 | 4.44 | 2.62 |
Loss (Gain) From Sale of Assets | -0 | -0 | - | - | -0.02 | - |
Asset Writedown & Restructuring Costs | - | - | - | 0.28 | 0.11 | 0.01 |
Loss (Gain) From Sale of Investments | -1.2 | -1.2 | -6.86 | -14.68 | -6.58 | -12.8 |
Provision & Write-off of Bad Debts | 0.42 | 0.42 | 2.22 | 0.64 | 1.4 | 3.28 |
Other Operating Activities | 154.04 | -28.75 | -33.48 | 8.77 | -15.57 | -4.53 |
Change in Accounts Receivable | -24.4 | -24.4 | -58.17 | -38.35 | -17.41 | -84.19 |
Change in Inventory | 9.59 | 9.59 | -72.01 | -11.87 | -47.07 | -28.77 |
Change in Accounts Payable | 123.55 | 123.55 | 285.27 | 78.49 | 67.14 | 38.99 |
Change in Other Net Operating Assets | 3.34 | 3.34 | 1.62 | -34.11 | 37.07 | 34.62 |
Operating Cash Flow | 814.89 | -28.78 | 38.2 | -232.75 | -370.34 | -454.62 |
Capital Expenditures | -181.46 | -181.47 | -95.69 | -62.6 | -88.62 | -70.74 |
Sale of Property, Plant & Equipment | - | - | - | 0 | 0 | 0 |
Investment in Securities | -493.92 | 116.12 | -1,764 | 115 | -182.1 | 380.01 |
Other Investing Activities | 41.36 | 9.71 | 14.86 | 12.44 | 6.66 | 17.39 |
Investing Cash Flow | -634.02 | -55.63 | -1,845 | 64.84 | -264.06 | 326.66 |
Long-Term Debt Issued | - | 1,127 | 1,288 | 983.8 | 561 | 171.4 |
Long-Term Debt Repaid | - | -1,022 | -1,150 | -644.19 | -242.77 | -64.91 |
Net Debt Issued (Repaid) | -20.31 | 104.92 | 138.43 | 339.61 | 318.23 | 106.49 |
Issuance of Common Stock | - | - | 0.34 | 1,192 | - | - |
Common Dividends Paid | -25.59 | -26.09 | -24.56 | -21.17 | -11.22 | -4.14 |
Other Financing Activities | -87.79 | -86.32 | -165.52 | -1.45 | -24.23 | -8.36 |
Financing Cash Flow | -133.69 | -7.5 | -51.32 | 1,509 | 282.79 | 93.99 |
Foreign Exchange Rate Adjustments | -5.18 | -0.69 | -2.3 | 0.22 | 4.07 | -1.44 |
Net Cash Flow | 42 | -92.61 | -1,861 | 1,342 | -347.54 | -35.41 |
Free Cash Flow | 633.43 | -210.25 | -57.49 | -295.35 | -458.97 | -525.36 |
Free Cash Flow Margin | 40.91% | -25.94% | -10.79% | -76.43% | -151.82% | -275.98% |
Free Cash Flow Per Share | 2.39 | -0.80 | -0.22 | -1.16 | -1.92 | -2.19 |
Cash Income Tax Paid | 85.82 | 80.56 | 51.24 | 15.67 | -17.55 | -30.33 |
Levered Free Cash Flow | 66.35 | -337.26 | -165.35 | -325.09 | -297.1 | -353.47 |
Unlevered Free Cash Flow | 81.48 | -322.14 | -147.3 | -310.99 | -289.58 | -350.71 |
Change in Working Capital | 108.09 | 108.09 | 152.83 | -9.58 | 36.84 | -42.98 |